1. Home
  2. BYON vs ERAS Comparison

BYON vs ERAS Comparison

Compare BYON & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BYON
  • ERAS
  • Stock Information
  • Founded
  • BYON 1997
  • ERAS 2018
  • Country
  • BYON United States
  • ERAS United States
  • Employees
  • BYON N/A
  • ERAS N/A
  • Industry
  • BYON Catalog/Specialty Distribution
  • ERAS Biotechnology: Pharmaceutical Preparations
  • Sector
  • BYON Consumer Discretionary
  • ERAS Health Care
  • Exchange
  • BYON Nasdaq
  • ERAS Nasdaq
  • Market Cap
  • BYON 468.4M
  • ERAS 484.4M
  • IPO Year
  • BYON N/A
  • ERAS 2021
  • Fundamental
  • Price
  • BYON $8.18
  • ERAS $1.41
  • Analyst Decision
  • BYON Hold
  • ERAS Strong Buy
  • Analyst Count
  • BYON 9
  • ERAS 6
  • Target Price
  • BYON $11.00
  • ERAS $4.83
  • AVG Volume (30 Days)
  • BYON 3.8M
  • ERAS 852.4K
  • Earning Date
  • BYON 07-28-2025
  • ERAS 08-11-2025
  • Dividend Yield
  • BYON N/A
  • ERAS N/A
  • EPS Growth
  • BYON N/A
  • ERAS N/A
  • EPS
  • BYON N/A
  • ERAS N/A
  • Revenue
  • BYON $1,128,578,000.00
  • ERAS N/A
  • Revenue This Year
  • BYON N/A
  • ERAS N/A
  • Revenue Next Year
  • BYON $13.21
  • ERAS N/A
  • P/E Ratio
  • BYON N/A
  • ERAS N/A
  • Revenue Growth
  • BYON N/A
  • ERAS N/A
  • 52 Week Low
  • BYON $3.54
  • ERAS $1.01
  • 52 Week High
  • BYON $12.24
  • ERAS $3.31
  • Technical
  • Relative Strength Index (RSI)
  • BYON 46.75
  • ERAS 40.59
  • Support Level
  • BYON $6.99
  • ERAS $1.34
  • Resistance Level
  • BYON $11.11
  • ERAS $1.81
  • Average True Range (ATR)
  • BYON 0.95
  • ERAS 0.12
  • MACD
  • BYON -0.19
  • ERAS -0.03
  • Stochastic Oscillator
  • BYON 25.00
  • ERAS 7.45

About BYON Beyond Inc.

Beyond Inc is an online retailer that provides products and services through websites. The company offers a broad number of products, including furniture, decor, area rugs, bedding and bath, home improvement, outdoor, and kitchen and dining items, BMMG (like books, magazines, CDs), electronics, and other items. The home and garden product line accounts for a material part of its total revenue. The company operates through a direct business that makes sales from the company's own inventory, and a partner business that sells merchandise from manufacturers, distributors, and other suppliers through the company's websites. The company generates the majority of its total revenue from partner business in terms of business format, and from the U.S. in terms of market.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Share on Social Networks: